First pediatric patient dosed with TSHA-102 in REVEAL Phase 1/2 trial for Rett syndrome

Taysha Gene Therapies, Inc.

First pediatric patient (female, 5-8 years, stage 3 Rett syndrome) dosed at RUSH University Medical Center.
MHRA authorized UK CTA for TSHA-102 in pediatric patients, expanding REVEAL into the UK.
Initial safety and efficacy data for cohort one (low dose, n=3) expected in mid-2024.
TSHA-102 uses miRARE technology to mediate MECP2 expression on a cell-by-cell basis.
TSHA-102 also has FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.